Enliven Therapeutics (ELVN) Operating Leases (2021 - 2022)
Enliven Therapeutics (ELVN) reported Operating Leases of $2.0 million for Q1 2022, up 233.39% on a YoY basis from $590000.0 in Q1 2021, and up 384.48% sequentially from $406000.0 in Q4 2021.
Enliven Therapeutics (ELVN) Operating Leases (2021 - 2022) Analysis & Trends
Enliven Therapeutics (ELVN) has 2 years of Operating Leases data on file, last reported at $2.0 million in Q1 2022.
- For the quarter ending Q1 2022, Operating Leases rose 233.39% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2022 stood at $2.0 million (up 233.39% YoY), and the FY2021 full-year result was $406000.0, changed N/A from the prior year.
- Operating Leases improved to $2.0 million in Q1 2022, from $406000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $2.0 million in Q1 2022 to a low of $406000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 406,000.00 |
| Sep 30, 2021 | 466,000.00 |
| Jun 30, 2021 | 528,000.00 |
| Mar 31, 2021 | 590,000.00 |